PLATELET SOLUTION FOR USE IN JOINT SURGERY

• US 20120258086A1
• Filed: 11/11/2010
• Published: 10/11/2012
• Est. Priority Date: 11/11/2009
• Status: Abandoned Application

• Current Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Original Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Inventors: Long, Marc, Song, Lin
• Application Number:
  US13/508,882
• Publication Number:
  US 20120258086A1
• Time in Patent Office: Days
• US Class Current: 424/93.72
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 38/1875 Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis

Abstract

The invention is directed to a method of accelerating healing in a joint comprising administering a platelet composition to the joint.

Claims

1. A method of enhancing recovery from joint surgery, comprising administering to the joint during surgery a composition comprising platelets in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein said platelets are autologous.

3. The method of claim 1, wherein said platelets are allogeneic.

4. The method of claim 1, wherein prior to being administered, said cells are homed to specifically bind one or more joint tissues, including synovial tissue, joint capsule, articulating cartilage, fibrocartilage (meniscus) tissue, ligament or tendon tissue.

5. The method of claim 1, wherein said carrier comprises plasma, serum, water for injection, fibrin, fibrinogen, hyaluronan, chemically modified hyaluronan, saline, phosphate buffered saline, chondroitin sulfate, glucosamine, mannosamine, proteoglycan, proteoglycan fragments, chitin, chitosan, or mixtures thereof.

6. The method of claim 1, wherein said composition further comprises a gelling agent, a hydrophilic agent, a surfactant, a lipid, a phospholipid, a surface-active phospholipid, or mixtures thereof.

7. The method of claim 1, wherein said composition further comprises a non-cellular therapeutic agent.

8. The method of claim 7, wherein said agent comprises a growth factor, cytokine, chemokine, hydrophilic compound, or an extracellular matrix compound.

9. The method of claim 7, wherein said agent is BMP-7.

10. The method of claim 1, wherein said joint is the knee, hip, shoulder, elbow, ankle, tarsal or metatarsal, wrist, spine, carpal or metacarpal, or temporal mandibular joint.

11. The method of claim 1, wherein the surgery is arthroscopic.

12. The method of claim 1, wherein the surgery is endoscopic.

13. The method of claim 1, wherein said composition is administered via injection prior to closing the joint or after the joint is closed.

14. The method of claim 1, wherein the joint is osteoarthritic.

15. The method of claim 1, wherein the joint exhibits one or more symptoms of inflammation.

16. The method of claim 1, wherein the platelets are co-administered with autologous or allogeneic stem cells.